All studies
RecruitingOBSERVATIONAL

Cognitive Health in Ageing Register: Investigational and Observational Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort (PRO) Longitudinal Study

The CHARIOT:PRO study (CPLS) is looking at how memory and thinking abilities change over time in people over 65, aiming to better understand the very early stages of Alzheimer's disease. We know that changes in the brain linked to Alzheimer's can start many years before symptoms appear. By regularly checking participants' thinking skills and looking at biological markers (like proteins in the blood), researchers hope to identify early warning signs. This is a long-term observational study, meaning participants attend regular visits for health checks and tests. The goal is to build on existing information and find ways to predict the disease, which could lead to new treatments or lifestyle advice to prevent or delay Alzheimer's in the future. It's about spotting changes early to make a big difference.

At a glance

Status
Recruiting
Sponsor
Imperial College London
Enrolment target
600
Start
17 Mar 2025
Estimated completion
01 Feb 2029

What is this study about?

Alzheimer's disease is the most common type of dementia, affecting about a million people in the UK. It's a condition where the brain's cells gradually get damaged. While it often affects older people, it's important to remember that dementia is *not* a normal part of ageing. In its early stages, symptoms like memory problems can be very mild and easily mistaken for simple forgetfulness. However, scientists now know that the changes in the brain that lead to Alzheimer's can begin more than 20 years before any noticeable symptoms appear.

These early brain changes involve two specific proteins: 'amyloid' and 'tau'. Amyloid can build up into clumps called 'plaques', and tau can form 'tangles' inside brain cells. These plaques and tangles disrupt how brain cells work, eventually damaging and destroying them. Currently, there isn't a cure for Alzheimer's, but understanding these early changes is key to finding ways to detect, diagnose, and treat the disease as early as possible.

The CHARIOT:PRO Longitudinal Study (CPLS) is an important observational study that follows 600 people over 65 for an extended period. All participants were previously screened in an earlier related study. The researchers will regularly assess their memory and thinking skills, and collect blood samples to look for 'biomarkers' – biological clues, like the amyloid protein – that might indicate the disease. By carefully observing these participants over many years, researchers aim to gather vital information about how Alzheimer's develops. They hope to identify really early signs or 'predictive markers' that could help doctors choose the most effective treatments or suggest lifestyle changes to prevent or delay the disease before it takes hold.

Key takeaways

  • A long-term study to understand early Alzheimer's disease.
  • Aims to identify changes in thinking and biological markers over time.
  • Involves regular visits, memory tests, and blood samples.
  • Hopes to find new ways to detect, prevent, or delay the disease.
  • Requires a study partner to provide additional information.

Who may be eligible?

This study is looking for people who are 65 years old or older. You must have been part of an earlier related study called CHARIOT:PRO Sub-Study (CPSS1), where you had specific tests for amyloid in your brain (either a PET scan or a special spinal fluid test). You also need to be able to speak, read, and write in English and have good enough hearing and eyesight to do the study tests.

It's important that you are willing and able to come to all the study visits and complete the assessments. You'll also need a 'study partner' – a relative, partner, or friend – who is over 18, fluent in English, and knows you well enough to provide helpful information about your daily life. They will need to come with you for the first visit.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you 65 years old or older?
  2. Did you complete the CHARIOT:PRO Sub-Study (CPSS1) amyloid screening?
  3. Can you speak, read, and write fluently in English?
  4. Do you have a study partner (friend/family) who can participate?
  5. Are you able and willing to attend regular study visits?
Answer every question to see your result.

What does participation involve?

If you take part in this study, you'll have several visits over about three years. Your first visit will be within eight weeks of starting, followed by visits every six months. During these visits, the study team will gather details about your health, any medications you take, your family's history of dementia, and your own memory and thinking. They’ll also take height and weight measurements.

You'll complete some specific tests of your thinking abilities, including memory and problem-solving. You’ll also fill out some questionnaires yourself. Blood samples will be taken once a year (at the start, after 12 months, 24 months, and 36 months). The study aims to follow participants for up to 12 years from their initial screening. You can stop participating at any time.

Potential risks and benefits

Taking part in this study won't directly benefit your health right now, as it's observational research, not a treatment study. However, the information you provide is incredibly valuable and will help researchers better understand Alzheimer's disease, potentially leading to future new ways to detect, prevent, or treat it. The risks of participating are generally low, mainly involving the minor discomfort of blood draws and the time commitment for visits. You have the full right to withdraw from the study at any time without giving a reason, and this will not affect your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Imperial College London
    Verified postcode
    London, United Kingdom· Recruiting

Common questions

What is an 'observational study'?

An observational study means researchers watch and collect information about people over time without giving them any new treatments or interventions.

What are 'biomarkers'?

Biomarkers are biological clues found in the body (like proteins in blood) that can indicate the presence of a disease or how it's progressing.

Will I receive information about my personal test results?

The study aims to gather general information to understand Alzheimer's disease, not to provide individual medical diagnoses or results.

What is the purpose of having a 'study partner'?

A study partner (e.g., family or friend) provides extra information about your daily life and memory, which can be very helpful for the researchers.

Who is funding this research?

This study is sponsored by Imperial College London and funded by Gates Ventures.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Cognitive Health in Ageing Register: Investigational and Obs…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.